Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab plus nivolumab versus nivolumab alone in previously untreated unresectable or metastatic melanoma
MOH_2018-07-26_002498Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Relatlimab + nivolumab with Nivolumab alone (2 arms). Started Jul 2018; status: active, not recruiting.
02
Drugs
relatlimabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2018-07-26_002498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-07-26_002498.